Search

Your search keyword '"Morichaut-Beauchant M"' showing total 2 results
Start Over Author "Morichaut-Beauchant M"
2 results on '"Morichaut-Beauchant M"'

1. Liver fibrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring

Author

Staub, F., Tournoux-Facon, C., Roumy, J., Chaigneau, C., Morichaut-Beauchant, M., Levillain, P., Prevost, C., Aubé, C., Lebigot, J., Oberti, F., Galtier, J. B., Laumonier, H., Trillaud, H., Bernard, P. H., Blanc, J. F., Sironneau, S., Machet, F., Drouillard, J., de Ledinghen, V., Couzigou, P., Foucher, P., Castéra, L., Tranquard, F., Bacq, Y., d’Altéroche, L., Ingrand, P., and Tasu, J. P.

Published
2009
Full Text
View/download PDF

2. Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatremia - a randomized, double-blind, placebo-controlled study

Author

Ginès P, Wong F, Watson H, Terg R, Bruha R, Zarski JP, Dudley F, NormoCAT study investigators: Angeli P, Angus P, Bilic A, Bronowicki JP, Chira C, Dobru D, Doffoel M, Fleig W, Fraticiu A, Gadano A, Gerbes A, Gheorge L, Goldis A, Grigorescu M, Horsmans Y, Hulek P, Lata J, Lonovics J, Manns M, Masliah C, Morichaut Beauchant M, Olteanu D, Pascu O, Planas R, Ramdani M, Ruiz del Arbol L, Siahmed SN, Stoica V, Ujszaszy L, Voiosu M.R., BERNARDI, MAURO, Ginès P, Wong F, Watson H, Terg R, Bruha R, Zarski JP, Dudley F, NormoCAT study investigators: Angeli P, Angus P, Bernardi M, Bilic A, Bronowicki JP, Chira C, Dobru D, Doffoel M, Fleig W, Fraticiu A, Gadano A, Gerbes A, Gheorge L, Goldis A, Grigorescu M, Horsmans Y, Hulek P, Lata J, Lonovics J, Manns M, Masliah C, Morichaut-Beauchant M, Olteanu D, Pascu O, Planas R, Ramdani M, Ruiz del Arbol L, Siahmed SN, Stoica V, Ujszaszy L, and Voiosu MR.

Subjects
Liver Cirrhosis, Male, medicine.medical_specialty, Cirrhosis, Morpholines, VASOPRESSIN V2 RECEPTORS, medicine.medical_treatment, Placebo-controlled study, Spironolactone, Placebo, Gastroenterology, chemistry.chemical_compound, Double-Blind Method, Furosemide, Internal medicine, Ascites, Humans, Medicine, Spiro Compounds, Pharmacology (medical), Prospective Studies, Diuretics, CIRRHOSIS, SATAVAPTAN, Aged, HYPONATREMIA, Hepatology, business.industry, Body Weight, Middle Aged, medicine.disease, Surgery, Drug Combinations, Satavaptan, Treatment Outcome, chemistry, Female, ASCITES, Diuretic, medicine.symptom, business, Hyponatremia, Antidiuretic Hormone Receptor Antagonists
Abstract

Aliment Pharmacol Ther 31, 834–845 Summary Background There is little information on the effects of vaptans in patients with cirrhosis. Aim To investigate the short-term effects of satavaptan, a selective vasopressin V2 receptor antagonist on ascites in cirrhosis without hyponatraemia. Methods A total of 148 patients with cirrhosis, ascites and serum sodium >130 mmol/L were included in a multicentre, double-blind, randomized, controlled study of 14 days comparing three fixed doses of satavaptan (5 mg, 12.5 mg or 25 mg once daily) vs. placebo. Average MELD scores were: 13.4, 12.3, 13.8 and 13.1 respectively. All patients received spironolactone 100 mg/day plus furosemide 20–25 mg/day. Results Satavaptan treatment was associated with a decrease in ascites (mean change in body weight was −0.36 kg (±3.03) for placebo vs. −2.46 kg (±3.11), −2.08 kg (±4.17) and −2.28 kg (±3.24) for the 5 mg, 12.5 mg and 25 mg doses respectively; P = 0.036, P = 0.041 and P = 0.036 for satavaptan 5, 12.5 and 25 mg/day vs. placebo respectively). Thirst and slight increases in serum sodium were more common in patients treated with satavaptan compared with placebo, while other adverse events were similar. Conclusions The administration satavaptan for a 14-day period is associated with reduction in ascites in patients with moderately severe cirrhosis without hyponatraemia under diuretic treatment.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results